Molecular Biomarkers & Diagnosis

Bal de Kier Joffé ED

Publications

• Research Article
  Oct2, BCL6, IRF8, OCAB and PU.1 in the Assessment of Prognosis in Diffuse Large B cell Lymphoma Patients
  Author(s): Rojas-Bilbao EA, Knott ME, Bal de Kier Joffé ED, Zerga ME, Nuñez M, Puricelli LI and Ranuncolo SMRojas-Bilbao EA, Knott ME, Bal de Kier Joffé ED, Zerga ME, Nuñez M, Puricelli LI and Ranuncolo SM
  
  Background: Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin Lymphoma in adults. This germinal center derived B cell lymphoma is a heterogeneous disease with a highly variable clinical course, currently treated with immune-chemotherapy. The International Prognosis Index (IPI) remains the main prognosis indicator. This highlights the absence of biomarkers suitable to provide molecular biology information to more accurately establish prognosis and predict treatment response in DLBCL patients. Methods: We determined the Oct2, BCL6, IRF8, OCAB and PU.1 transcription factors expression by immunohistochemistry in 73 DLBCL lymph node biopsies to address their potential as prognosis biomarkers in DLBCL patients. These molecules exhibit well-known key roles in the germinal center development. Results: .. Read More»
  DOI: 10.4172/2155-9929.1000276

  Abstract PDF